Since the continued elevation of ET-1 could contribute to the above mentioned detrimental ophthalmologic effects, the antagonists of ET receptors, ET-1 neutralizing antibodies or drugs blocking ET-1 synthesis are now considered as potential tools in the pharmacological treatment of glaucoma[18, 19]. Here, EDN1 is linked to glaucoma.